Study inspection of preclinical safety evaluation of drug is an important responsibility for quality assurance unit (QAU) with good laboratory practice (GLP).

The biomarkers of myocardial injury are used widely in clinical diagnosis of heart diseases. However, application of the biomarker in drug preclinical safety evaluation is relatively less.